Abstract
Pain management using opioid analgesics strives to achieve three goals: maximum efficacy, minimal risk of tolerance and physical dependence, and negligible side effects. Following the cloning of opioid and nociceptin receptors, novel ligands can be designed to target specific residues of these membrane proteins with the goal of improving efficacy and reducing side effects through selectivity. For the most part, ligand design has focused on binding sites located in the transmembrane region of the receptors, and has ignored the extracellular domains. In this review, we discuss the evidence for the interaction of the extracellular regions with opioids and show how computational biology tools can be used to model these domains for use in drug discovery. A computational model of the κ-opioid receptor which includes the loop regions is presented. The model combines knowledge-based information, bioinformatics and computational tools to identify regions of the extracellular loop domains that can be targeted by drug design.
Keywords: g-protein coupled receptors(gpcr), endogenous ligands, extracellular loop (el), third transmembrane helix (tm3), opioid/nociceptin receptors, enkephalins, analgesia, mutagenesis, drosophila, cysteine
Current Topics in Medicinal Chemistry
Title: The Function of the Extracellular Regions in Opioid Receptor Binding: Insights from Computational Biology
Volume: 5 Issue: 3
Author(s): M. Germana Paterlini
Affiliation:
Keywords: g-protein coupled receptors(gpcr), endogenous ligands, extracellular loop (el), third transmembrane helix (tm3), opioid/nociceptin receptors, enkephalins, analgesia, mutagenesis, drosophila, cysteine
Abstract: Pain management using opioid analgesics strives to achieve three goals: maximum efficacy, minimal risk of tolerance and physical dependence, and negligible side effects. Following the cloning of opioid and nociceptin receptors, novel ligands can be designed to target specific residues of these membrane proteins with the goal of improving efficacy and reducing side effects through selectivity. For the most part, ligand design has focused on binding sites located in the transmembrane region of the receptors, and has ignored the extracellular domains. In this review, we discuss the evidence for the interaction of the extracellular regions with opioids and show how computational biology tools can be used to model these domains for use in drug discovery. A computational model of the κ-opioid receptor which includes the loop regions is presented. The model combines knowledge-based information, bioinformatics and computational tools to identify regions of the extracellular loop domains that can be targeted by drug design.
Export Options
About this article
Cite this article as:
Paterlini Germana M., The Function of the Extracellular Regions in Opioid Receptor Binding: Insights from Computational Biology, Current Topics in Medicinal Chemistry 2005; 5 (3) . https://dx.doi.org/10.2174/1568026053544579
DOI https://dx.doi.org/10.2174/1568026053544579 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vitamin D Levels in Middle-Aged Patients with Obstructive Sleep Apnoea Syndrome
Current Vascular Pharmacology Evidence for Altered LRP/RAGE Expression in Alzheimer Lesion Pathogenesis
Current Alzheimer Research Editorial from Editor-in-Chief: Are Implanted Upper Airway Stimulation Devices for the Treatment of Obstructive Sleep Apnea Ready for Primetime?
Current Respiratory Medicine Reviews Nanomagnets-From Fundamental Physics to Biomedicine
Current Nanoscience Molecular Effects of L-dopa Therapy in Parkinson’s Disease
Current Genomics Microfluidics for Monitoring Oxidative Stress and Antioxidant Capacity
Current Analytical Chemistry Acamprosate: A Prototypic Neuromodulator in the Treatment of Alcohol Dependence
CNS & Neurological Disorders - Drug Targets Delivery of Therapeutic Proteins: Challenges and Strategies
Current Drug Targets Advances in the Use of Stem Cells and Tissue Engineering Applications in Bone Repair
Current Stem Cell Research & Therapy Time Perception Distortion in Neuropsychiatric and Neurological Disorders
CNS & Neurological Disorders - Drug Targets Cationized Albumin Conjugated Solid Lipid Nanoparticles as Vectors for Brain Delivery of an Anti-Cancer Drug
Current Nanoscience Strategies for the Design of Potent and Selective Kinase Inhibitors
Current Pharmaceutical Design Towards a Reconceptualization of Striatal Interactions Between Glutamatergic and Dopaminergic Neurotransmission and Their Contribution to the Production of Movements
Current Neuropharmacology Hutchinson-Gilford Progeria Syndrome (Hgps) and Application of Gene Therapy Based Crispr/Cas Technology as A Promising Innovative Treatment Approach
Recent Patents on Biotechnology Cannabinoid Modulation of Neuroinflammatory Disorders
Current Neuropharmacology Mitochondria: Prospective Targets for Neuroprotection in Parkinson's Disease
Current Pharmaceutical Design Extrahepatic Metabolism may Complicate the IVIVC in Rats
Drug Metabolism Letters Etiopathogenesis and Treatment of Parkinsons Disease
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Neuroinflammation a Common Link in Neurodegenerative Neurological and Psychiatric Disorders)
Current Pharmaceutical Design Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon
CNS & Neurological Disorders - Drug Targets